GRAIL, Inc.
GRAIL, Inc. develops and commercializes Galleri, a blood-based multi-cancer early detection test designed to screen for multiple cancers from a single blood draw. The company operates a clinical laboratory and sells primarily through physicians, health systems, employers, payors, digital health platforms, life insurers, and other partners, with a business model centered on expanding access to the test in the U.S. and selected international markets.
Fiscal year 2025 · change from previous year
Development 2023–2025
Business
Share of revenueBlood-based cancer screening test sold to patients through clinical and partner channels.
Commercial access to Galleri outside the U.S. through local and regional partners.
Consumer-facing distribution partnerships that expand awareness and test reach.
Channel partnerships that place Galleri as a preventive health benefit.
Research-use-only offerings and biopharmaceutical research partnerships.
Products
Reported · share of revenue- Screening Revenue94.2 %
- Developmental Services Revenue5.8 %
Source: 10-K FY2025, revenue the company reports per product line (SEC XBRL). Shares are of the lines shown and add up to 100 %.
Customers
GRAIL sells to a mix of healthcare and consumer-health channels rather than a single end market. Core buyers and influencers include primary care physicians, health systems, employers, payors, life insurance providers, digital health platforms, and research partners, all of whom help drive test adoption and patient access.
They order Galleri for patients in a pre-reimbursement setting and are central to test adoption.
They run pilots and broader screening programs to integrate Galleri into care pathways.
They buy access as a preventive health benefit to support workforce wellness.
They evaluate Galleri for coverage based on clinical and economic evidence.
They offer Galleri as a member benefit to support early detection and prevention.
They distribute Galleri to cash-paying consumers through wellness-oriented offerings.
Strategy
GRAIL’s strategy is to expand Galleri adoption through value-oriented partnerships that reduce customer acquisition cost and broaden access. The company is also building evidence for clinical and economic utility so that reimbursement, channel expansion, and international market entry can scale more efficiently over time.
Revenue depends on increasing test volume before broad reimbursement is in place.
Evidence supports reimbursement decisions and improves conversion from pilots to recurring use.
Local partners can accelerate market entry while reducing direct operating burden.
Patent and know-how protection supports differentiation in a technically complex market.
Geography
GRAIL generates most screening revenue in the United States, where Galleri is sold primarily through physician and partner channels. Outside the U.S., access is built through local and regional partners, but expansion depends on regulatory clearance in each market, making international growth slower and more selective.
Risks
GRAIL faces commercialization risk because Galleri is not broadly reimbursed and demand depends on proving clinical and economic value. The company also faces regulatory, cybersecurity, supply chain, and intellectual property risks, all of which are especially important for a diagnostics business that relies on sensitive patient data, laboratory operations, and partner networks.
- Limited reimbursement for GalleriImpact: HighLikelihood: High
Without broad coverage, demand depends on self-pay and selective partner channels.
Exposure: U.S. commercialization
- Cybersecurity and data privacy incidentsImpact: HighLikelihood: Medium
The business handles sensitive health data and depends on secure lab and partner systems.
Exposure: Clinical laboratory and digital channels
- Supply chain concentration and continuity riskImpact: HighLikelihood: Medium
Single-source or sole-source inputs could disrupt continuous laboratory operations.
Exposure: Reagents and raw materials
- Regulatory clearance delays outside the United StatesImpact: MediumLikelihood: Low
International market entry is contingent on local approvals for the test.
Exposure: International expansion
- Intellectual property expiration and disputesImpact: MediumLikelihood: Low
Core licensed patents begin expiring in 2027, which may pressure long-term exclusivity.
Exposure: Galleri and product pipeline
Accounting
Judgemental itemsRevenue is booked when results are delivered, so timing depends on test completion and reporting.
Impact: Quarterly revenue volatility
Expected collections may be below invoiced amounts due to price concessions.
Impact: Revenue reserve estimates and gross margin
Larger customers and international distributors often receive lower contractual pricing.
Impact: Average selling price and channel margin
The company carries acquisition-related goodwill and must test for impairment annually or on trigger events.
Impact: Potential non-cash charges to earnings
Licensing agreements create fixed annual royalty obligations regardless of sales volume.
Impact: Future expense and cash outflow
Similar listed companies
Publicly listed companies with a comparable business focus.
Guardant Health, Inc.
GH · Services-Medical Laboratories
Guardant Health is a precision oncology company built around blood- and tissue-based cancer tests, real-world data, and AI analytics.
Myriad Genetics, Inc
MYGN · In Vitro & In Vivo Diagnostic Substances
Myriad Genetics develops and commercializes molecular diagnostic tests that help clinicians assess disease risk, guide treatment selection, and support earlier…
BriaCell Therapeutics Corp.
BCTXZ · Pharmaceutical Preparations
Veracyte, Inc
VCYT · Services-Medical Laboratories
Veracyte is a U.S.-based molecular diagnostics company that develops and commercializes genomic tests used in cancer and other disease areas.
Geron Corporation
GERN · Pharmaceutical Preparations
Geron Corp is a U.S.-based biopharmaceutical company focused on developing and commercializing imetelstat, marketed as RYTELO, for patients with lower-risk myelodysplastic syndromes.
GRI Bio, Inc.
GRI · Pharmaceutical Preparations
Last updated: 24/09/2026